Epidural Magnesium Sulfate for Post-thoracotomy Pain Control

The Effect of Adjuvant Epidural Magnesium Sulfate to Bupivacaine and Morphine on Post-thoracotomy Pain Control: A Randomized Double Blind Clinical Trial Study

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03343548

Enrollment

Registered

2017-11-17

Start date

2016-12-31

Completion date

2017-12-31

Last updated

2018-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain

Brief summary

Pain after thoracotomy is very severe and may cause pulmonary complications. Thoracic epidural analgesia has greatly decreased the pain experience and its consequences. However, new ways of decreasing post-operative opioid drugs consumption is an important issue of research. We aim to evaluate the effect of adding epidural magnesium sulfate to bupivacaine and morphine on pain control and the amount of opioid consumption after thoracotomy. Eighty patients undergoing thoracotomy at a tertiary cardiothoracic referral center will be enrolled in a randomized double blind trial. Patients randomly will be allocated in two groups. Bupivacaine (12.5 mg) plus morphine (2 mg) will be administered epidurally for all patients at the end of operation. Patients in group I will be received epidural magnesium sulfate (50 mg) and patients in Group II will be received normal saline as an adjuvant. Visual analog scale (VAS) score and the amount of morphine consumption will be measured during 24 hours post-operation.

Interventions

DRUGmagnesium sulfate

2cc of magnesium sulfate ( 50%) will be administered epidurally

DRUGnormal saline

2cc of normal saline will be administered epidurally

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender

ALL

Age

16 Years to 85 Years

Healthy volunteers

Inclusion criteria

* American Society of Anesthesiologists physical statuses I-III * Undergoing thoracotomy

Exclusion criteria

* Known hypersensitivity to magnesium sulfate * Renal failure * Hepatic dysfunction * Severe obesity * Psychotic or neurologic diseases * Currently taking opioid or calcium channel blocker * AV block degree II or III * Refused to participate in trial

Design outcomes

Primary

Measure	Time frame	Description
severity of post-thoracotomy pain	24 hours after thoracotomy	VAS (visual analog scale: 0-10 cm (0 cm = no pain and 10 cm = the worst pain)) score will be measured

Countries

Iran

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026